Natural killer cell adoptive transfer therapy: Exploiting the first line of defense against cancer

Cancer Journal (United States)

Volumn 21, Issue 6, 2015, Pages 486-491

  Davis, Zachary B ^a   Felices, Martin ^a   Verneris, Michael R ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Adoptive transfer therapy; Antitumor functions; natural killer (NK) cells; Prospective therapeutic enhancements; Tumor microenvironment

Indexed keywords

ADOPTIVE TRANSFER; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; HUMAN; MEMORY CELL; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; ADOPTIVE IMMUNOTHERAPY; IMMUNOLOGY; NEOPLASMS; PROCEDURES;

ADOPTIVE TRANSFER; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 84948392976     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000156     Document Type: Review

References (82)

1. Herberman RB, NunnME, HoldenHT, et al. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 1975; 16: 230-239.
2. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouseMoloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975; 5: 112-117.
3. Riccardi C, Santoni A, Barlozzari T, et al. In vivo natural reactivity of mice against tumor cells. Int J Cancer. 1980; 25: 475-486.
4. Barlozzari T, Reynolds CW, Herberman RB. In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol. 1983; 131: 1024-1027.
5. Lanier LL. Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell. 1998; 92: 705-707.
6. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008; 9: 495-502.
7. Anfossi N, André P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006; 25: 331-342.
8. Lanier LL. Activating and inhibitory NK cell receptors. Adv Exp Med Biol. 1998; 452: 13-18.
9. Roder JC, Pross HF. The biology of the human natural killer cell. J Clin Immunol. 1982; 2: 249-263.
10. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001; 1: 41-49.
11. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol. 2001; 29: 1157-1168.
12. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007; 7: 329-339.
13. Waldhauer I, Steinle A.NKcells and cancer immunosurveillance. Oncogene. 2008; 27: 5932-5943.
14. Smyth MJ, Hayakawa Y, Takeda K, et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002; 2: 850-861.
15. + and Fas- tumor cells. Blood. 1998; 92: 4248-4255.
16. Screpanti V, Wallin RP, Ljunggren HG, et al. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol. 2001; 167: 2068-2073.
17. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001; 7: 94-100.
18. Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol. 2002; 168: 1356-1361.
19. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood. 2001; 97: 192-197.
20. +) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood. 2002; 99: 1259-1266.
21. Pietra G, Manzini C, Rivara S, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 2012; 72: 1407-1415.
22. Vitale M, Cantoni C, Pietra G, et al. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol. 2014; 44: 1582-1592.
23. Della Chiesa M, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2Dactivating receptors and regulates NK-cell function. Blood. 2006; 108: 4118-4125.
24. Sutlu T, Alici E.Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J InternMed. 2009; 266: 154-181.
25. Farag SS, CaligiuriMA. Cytokinemodulation of the innate immune system in the treatment of leukemia and lymphoma. Adv Pharmacol. 2004; 51: 295-318.
26. Smyth MJ, Cretney E, Kershaw MH, et al. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004; 202: 275-293.
27. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 2005; 86: 209-239.
28. Rosenberg SA. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am. 2000; 6(suppl 1): S2-S7.
29. Burns LJ, Weisdorf DJ, DeFor TE, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant. 2003; 32: 177-186.
30. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J ExpMed. 2005; 202: 1075-1085.
31. Rodella L, Zamai L, Rezzani R, et al. Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br J Haematol. 2001; 115: 442-450.
32. VernerisMR. Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL. Hematology Am Soc Hematol Educ Program. 2013; 2013: 335-341.
33. Ruggeri L, CapanniM, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295: 2097-2100.
34. Ruggeri L, Mancusi A, Perruccio K, et al. Natural killer cell alloreactivity for leukemia therapy. J Immunother. 2005; 28: 175-182.
35. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105: 3051-3057.
36. Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014; 123: 3855-3863.
37. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009; 113: 726-732.
38. + NK progenitor. Blood. 1994; 83: 2594-2601.
39. + hematopoietic progenitor cells. Blood. 1996; 87: 2632-2640.
40. Grzywacz B, Kataria N, Kataria N, et al. Natural killer-cell differentiation by myeloid progenitors. Blood. 2011; 117: 3548-3558.
41. Woll PS, Martin CH, Miller JS, et al. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol. 2005; 175: 5095-5103.
42. Woll PS, Grzywacz B, Tian X, et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood. 2009; 113: 6094-6101.
43. Knorr DA, Kaufman DS. Pluripotent stem cell-derived natural killer cells for cancer therapy. Transl Res. 2010; 156: 147-154.
44. Cheng M, Zhang J, Jiang W, et al. Natural killer cell lines in tumor immunotherapy. Front Med. 2012; 6: 56-66.
45. Tonn T, Becker S, Esser R, et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.J Hematother StemCell Res. 2001; 10: 535-544.
46. Klingemann HG. Natural killer cell-based immunotherapeutic strategies. Cytotherapy. 2005; 7: 16-22.
47. Malmberg KJ, Bryceson YT, CarlstenM, et al. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother. 2008; 57: 1541-1552.
48. Suck G, Branch DR, SmythMJ, et al. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol. 2005; 33: 1160-1171.
49. Suck G, Branch DR, Keating A. Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol. 2006; 82: 355-361.
50. Robertson MJ, Cochran KJ, Cameron C, et al. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996; 24: 406-415.
51. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature. 2009; 457: 557-561.
52. Romee R, Schneider SE, Leong JW, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012; 120: 4751-4760.
53. +NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011; 108: 14725-14732.
54. +) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol. 2012; 189: 5082-5088.
55. + natural killer cells with potent function. Blood. 2012; 119: 2665-2674.
56. Davis ZB, Cooley SA, Cichocki F, et al. Adaptive natural killer cell and killer cell immunoglobulin-like receptor-expressing T cell responses are induced by cytomegalovirus and are associated with protection against cytomegalovirus reactivation after allogeneic donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015; 21: 1653-1662.
57. + T cells into innate-like effector cells with antitumor activity. Oncoimmunology. 2013; 2: e26442.
58. Ni J, Miller M, Stojanovic A, et al. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med. 2012; 209: 2351-2365.
59. Cooper MA, Elliott JM, Keyel PA, et al. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009; 106: 1915-1919.
60. Borrego F, Lopez-Beltran A, Peña J, et al. Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C. Cell Immunol. 1994; 158: 208-217.
61. Edsparr K, Speetjens FM, Mulder-Stapel A, et al. Effects of IL-2 on MMP expression in freshly isolated human NK cells and the IL-2-independent NK cell line YT. J Immunother. 2010; 33: 475-481.
62. +) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia. 2007; 21: 356-359; author reply 359.
63. Harrison D, Phillips JH, Lanier LL. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II). J Immunol. 1991; 147: 3459-3465.
64. Liu Q, SunY, Rihn S, et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol. 2009; 83: 8705-8712.
65. Romee R, Foley B, Lenvik T, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013; 121: 3599-3608.
66. Zhou Q, Gil-Krzewska A, Peruzzi G, et al. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Clin Exp Immunol. 2013; 173: 131-139.
67. Ferrini S, Cambiaggi A, Cantoni C, et al. Targeting of TorNKlymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules. Int J Cancer Suppl. 1992; 7: 15-18.
68. Foley B, FelicesM, Cichocki F, et al. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev. 2014; 258: 45-63.
69. Moore GL, Bautista C, Pong E, et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs. 2011; 3: 546-557.
70. + targets. Blood. 2014; 123: 3016-3026.
71. Gleason MK, Verneris MR, Todhunter DA, et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012; 11: 2674-2684.
72. Vallera DA, Zhang B, Gleason MK, et al. Heterodimeric bispecific singlechain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm. 2013; 28: 274-282.
73. Wiernik A, Foley B, Zhang B, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16x33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013; 19: 3844-3855.
74. Benson DM Jr, Cohen AD, Jagannath S, et al. A phase I trial of the anti- KIR antibody IPH2101 and lenalidomide in patients with relapsed/ refractory multiple myeloma. Clin Cancer Res. 2015; 21: 4055-4061.
75. KordeN, Carlsten M, LeeMJ, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica. 2014; 99: e81-e83.
76. BensonDMJr, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012; 120: 4324-4333.
77. Benson DMJr, Bakan CE, Zhang S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011; 118: 6387-6391.
78. Nguyen S, Dhedin N, Vernant JP, et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005; 105: 4135-4142.
79. Godal R, Bachanova V, Gleason M, et al. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant. 2010; 16: 612-621.
80. Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versusmultiplemyeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010; 116: 2286-2294.
81. CarlstenM, Childs RW. Geneticmanipulation ofNKcells for cancer immunotherapy: techniques and clinical implications. Front Immunol. 2015; 6: 266.
82. Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol. 2015; 6: 195.